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ABSTRACT
Objective: To assess the long-term healthcare costs and 
health outcomes in association with the access to new direct-acting 
antivirals (DAAs), during the first year of the National Strategic Plan 
for Chronic Hepatitis C (SPCHC) in patients with chronic hepatitis 
C (CHC) in Spain.
Methods: A decision tree and a lifetime Markov model were 
developed to simulate the natural history, morbidity, and mortality 
of a cohort of 51,900 patients with CHC before (pre-DAA 
strategy) and after (post-DAA strategy) access to DAAs, following 
SPCHC approval. The percentage of patients treated, transition 
probabilities, disease management costs, health state utility values, 
sustained virologic response rates and treatment costs were 
obtained from the literature and published data from Spain. The 
results were expressed in terms of costs (€, 2016), quality-adjusted 
life years (QALYs) and prevention of clinical events, with an annual 
discount rate of 3%.
Results: The post-DAA strategy would prevent 8,667 cases of 
decompensated cirrhosis, 5,471 cases of hepatocellular carcinoma, 
1,137 liver transplants and 9,608 liver-related deaths. The cohort 
of 51,900 patients would require investments of 1,606 and 
1,230 million euros with the post-DAA and pre-DAA strategies, 
respectively. This would produce 819,674 and 665,703 QALYs.
Conclusions: The use of new DAA-based treatments in 
CHC patients during the first year after the implementation of the 
SPCHC significantly reduced long-term morbidity and mortality and 
increased quality of life; demonstrating that this plan is an efficient 
use of public health resources.
Key words: Direct action antiviral agents. Chronic hepatitis C. 
Strategic plan for hepatitis C management. Social value. Innovation. 
Efficacy.
INTRODUCTION 
Studies performed before the implementation of the 
National Strategic Plan for Chronic Hepatitis C (SPCHC) 
estimated that the prevalence of hepatitis C virus (HCV) 
infection in Spain was 1.6%. This corresponds to approx-
imately 475,000 people, of whom only 40% were diag-
nosed (1). Chronic hepatitis C (CHC) is characterized 
by the development of liver fibrosis, which leads to liver 
cirrhosis in up to 25% of patients (2). In most cases, this 
progression is slow and completely asymptomatic. How-
ever, once liver cirrhosis develops, the annual probability 
of developing clinically decompensated cirrhosis (DC) is 
4% and the probability of developing hepatocellular car-
cinoma (HCC) is 1.5% (3). These conditions could even-
tually require liver transplantation (LT) or result in death. 
Additionally, the delayed diagnosis and treatment of CHC 
facilitates viral transmission among the population.
From 1990 to 2013, the worldwide mortality rates relat-
ed to cirrhosis and HCC caused by hepatitis C increased by 
67% and 291%, respectively (4). Therefore, HCC resulting 
from CHC represents a major health burden (5) and is now 
among one of the eight pathologies that cause over 100,000 
annual deaths worldwide. In Spain, the estimated number 
of total deaths attributable to HCV infection was 4,342 in 
2000 from a total of 360,391 deaths (6), accounting for 
1.5% of the deaths in that year. A premature death rep-
resents a quantifiable loss of life years. In 2006, the burden 
of CHC in Spain in terms of years of life lost ranged from 
63,753 to 73,790 years (7). Therefore, CHC was the sev-
enth leading cause of years of life lost. Moreover, when 
life years with disability are added to years of life lost, the 
resulting disability-adjusted life years (DALYs) loss ranges 
from 71,122 to 81,336 (7). 
The efficacy of oral antiviral therapies based on pegylat-
ed IFNα (peg-IFN) that have been developed during the 
last decade has had a relatively low impact on the burden 
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of HCV infection (8). Modelling studies conducted using 
data from a Spanish population evaluated outcomes fol-
lowing the use of peg-IFN and ribavirin (peg-IFN/RBV) or 
triple therapy with an HCV protease inhibitor (boceprevir 
or telaprevir) and peg-IFN/RBV. A study showed that there 
were reductions in mortality (ranging from 8.1% to 10.3%) 
and cirrhosis incidence (ranging from 13.8% to 18.4%) 
only in patients infected with genotype 1 HCV (9). 
The burden of CHC in Spain requires the use of innova-
tive health interventions with improved efficacy and safety, 
such as new direct-acting antiviral agents (DAAs) in peg-
IFN free regimens. These therapeutics have achieved > 
95% infection cure rates (10-12) and have the potential to 
rapidly reduce the burden of the disease. 
In Spain, the institutional response to the introduction of 
new DAAs regimens aimed to ensure access to treatment 
in a way that remains sustainable for the health system. 
These goals were pursued via the development and rapid 
implementation of the SPCHC in 2015 (13). The SPCHC 
states that all patients are eligible for high-effective DAA 
therapy. However, due to the extent of the disease in Spain, 
it was decided that patients with advanced liver fibrosis 
(including stages F2-F4), patients on transplant waiting 
lists and those with recurrent HCV infection should be 
prioritized for these treatments. Other European countries 
have implemented similar measures to strategically pri-
oritize patients for DAAs treatment by categorizing them 
into subgroups (14).
Given that economic resources are limited and that the 
sustainability of public health systems must be ensured 
in decision-making, it is necessary to evaluate the clin-
ical evidence and cost-effectiveness of innovative ther-
apeutics. When assessing treatment priorities, the prin-
cipal question that must be addressed in an economic 
evaluation is whether the overall costs of an intervention 
are sufficiently counterbalanced by the health outcomes 
achieved. These factors should always be compared with 
the standard alternatives that are available at the time of 
decision-making. In addition, patient clinical characteris-
tics (15,16) must be considered as well as the economic 
and National Healthcare System of each country (17). To 
address these issues, we first assessed the extent to which 
new DAAs prevent the hepatic complications of disease 
progression (e.g., DC, HCC, LT, and liver disease-relat-
ed mortality). It is also important to evaluate the corre-
sponding direct and indirect costs and the healthcare and 
non-healthcare resources used by patients with and with-
out a sustained virologic response (SVR) to HCV therapy; 
such as patients without access to treatment or for whom 
treatment was not effective (18).
The aim of this study was to evaluate long-term health 
costs and outcomes during the first year (2015) after appli-
cation of the SPCHC using new DAAs (post-DAA) in 
patients infected with CHC (≥ F2) from the perspective 
of the National Health System in Spain. These data were 
compared to those obtained when using previously avail-
able regimens (pre-DAA).
METHODS
We compared incremental long-term health outcomes and costs 
generated throughout the patient’s life on the use of new DAAs during 
the first year (2015) after implementation of SPCHC (post-DAA strat-
egy) versus those produced using previously available regimens based 
on peg-interferon plus ribavirin and telaprevir or boceprevir prior to 
the SPCHC (pre-DAA strategy), in CHC patients. 
The analysis included 51,900 CHC patients with significant or 
advanced fibrosis (≥ stage F2) (13) with an average age of 52 (19). 
All patients were treated according to the European Medicines Agen-
cy (EMA) approved combinations of DAAs IFN free regimens (13). 
A decision tree was designed and patients were separated based on 
whether they were treated or untreated and were proportionally dis-
tributed according to their clinical characteristics (genotype, degree 
of fibrosis, treatment-naïve or previously treated status) (Table 1). 
The tree was used to calculate the global SVR rates for each fibrosis 
stage, regardless of genotype. In total, 73% of the patients were treat-
ed using the post-DAA strategy and 19% were treated with the pre-
DAA strategy (20). SVR rates according to clinical characteristics 
were obtained from clinical trials or the most relevant studies of each 
treatment included in the analysis (21). The remaining patient clin-
ical characteristics included in the decision tree were obtained from 
the literature and published Spanish data and are shown in table 1.
A lifetime Markov model was developed based on previously 
validated models (19,21) in order to project and analyze disease 
progression; during which patients could have transitioned annu-
ally from one stage to another depending on the probabilities of 
developing DC or HCC, undergoing LT or moving to post-LT status. 
Disease progression was monitored until death. Annual probabil-
ities were obtained from the literature (22,24,29) (Table 1). SVR 
patients with stage F2 fibrosis were considered as no longer at risk 
of disease progression, whereas those with stage F3 or F4 fibrosis 
remained at risk of developing DC or HCC. In addition, according 
to the published data, the achievement of an SVR following treat-
ment in some cirrhotic patients could lead to the fibrosis regression 
(23). Therefore, this transition was considered in the simulation of 
disease for patients in the SVR F4 state. The patient quality of life 
for each health state is represented by utility measures obtained from 
the literature (24). Disutility was also considered during treatment 
administration (30) (Table 1). 
With regard to the pharmacological cost of the pre-DAA strategy, 
an average cost of €15,003 per patient was calculated (31) within the 
Spanish Health System, including the application of corresponding 
deductions. For the post-DAA strategy, the overall pharmacological 
cost of treating all patients with CHC in 2015 with the new DAA 
strategies was €1,094 million (32). For both strategies, the average 
cost of treatment monitoring was €1,257 for the post-DAA strategy 
and €2,371 for the pre-DAA strategy. These costs included different 
treatment durations (8, 12, 24, or 48 weeks) and were calculated 
from published data (33). The annual health costs associated with 
each health state were obtained from published data (30,33). All 
costs are expressed in Euros and were updated in 2016.
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Table 1. Parameters used in the modelling of chronic hepatitis C 
Parameter Value Reference
Distribution of patients according to their characteristics
Genotype
 GT 1, % 69.32 (13)
 GT 2, % 2.27 (13)
 GT 3, % 15.91 (13)
 GT 4, % 12.50 (13)
Fibrosis stages (13)
 F2, % 31.48 (13)
 F3, % 27.78 (13)
 F4, % 40.74 (13)
Treatment status
 Naïve, % 41.42 (19)
 Pretreated patients, % 58.58 (19)
Estimated SVR rates
 Fibrosis stages  Pre-DAA (ranges)  Post-DAA (ranges)
  F2, %   55.0-75.2   93.9-97.1
Calculated from register studies or trials  F3, %   55.0-75.2   93.2-96.9
  F4, %   55.0-75.2   87.4-96.3
Annual transition probabilities Value Reference
F2-F3 0.12 (23)
F3-F4 0.116 (23)
F3-HCC 0.011 (28)
SVR F3-HCC 0.00264 (28)
F4-DC 0.04 (27)
F4-HCC 0.015 (22)
SVR F4-DC 0.003 (28)
SVR F4-HCC 0.005 (28)
SVR F4-Regr. HC 0.055 (25)
DC-HCC 0.068 (26)
DC-LT 0.023 (24)
DC-Liver-related death 0.138 (26)
CHC-LT 0.04 (24)
CHC-Liver-related death 0.43 (22)
LT-Post-LT 1.00 Assumption
LT-Liver-related death 0.21 (22)
Post-LT-Liver-related death 0.057 (22)
Annual health state utility values Cost of the health states
Health states Utility values Reference Costs Reference
F2 0.92 (23) €305 (32)
F3 0.79 (23) €305 (32)
F4 0.76 (23) €556 (32)
(Continue in the next page)
812 J. TURNES ET AL. Rev esp enfeRm Dig
Rev esp enfeRm Dig 2017;109(12):809-817
Analysis of health costs and outcomes
Health outcomes were measured in terms of quality-adjusted life 
years (QALYs), which were calculated by multiplying the years of life 
gained with each strategy by the utility value. This measure reflects a 
patients´ preference for each health state (34). The incremental cost 
was calculated as the difference in total cost (drug, monitoring, and 
management of complications) between one strategy and another.
In order to calculate the present value of future costs and health 
outcomes and compare them in terms of a net present value, a dis-
count rate of 3% was applied (35). However, because there is debate 
regarding whether health outcomes and cost should be discounted, 
and if this discount is applied at what rate and point in time, data on 
costs and health outcomes without the discount rate (0%) applied 
have also been included in some cases (36). 
In order to provide a monetary estimate of the societal value of 
quality of life adjusted survival gain, the number of incremental 
QALYs obtained with the post-DAA strategy versus the pre-DAA 
strategy was multiplied by different values of cost per QALY or 
willingness to pay (37), such as 20,000, 25,000 and 30,000 euros 
per QALY (37,38). 
Sensitivity analysis
Different one-way sensitivity analyses (OWSA) were performed 
for each minimum and maximum value for the parameters that gen-
erated a greater uncertainty of the analyzed results. These parameters 
included the SVR rates for each fibrosis stage considering the ranges 
of values obtained in the decision tree (87.4-93.2% for post-DAA 
and 55.0-75.2% for pre-DAA) and assuming the ranges of values 
of the percentage of patients treated (66-100% for post-DAA and 
17-21% for pre-DAA), drug costs (± 20%) and LT costs (± 20%).
RESULTS
Figure 1 shows the overall cost and health outcome 
expressed as QALYs for the 51,900 patients evaluated. 
The incremental cost of the post-DAA strategy compared 
with the pre-DAA strategy is €375 million. For the period 
in which access to new DAAs was considered, that is, in 
the first year of SPCHC implementation, 153,970 addi-
tional QALYs were obtained with the post-DAA strategy 
compared to the pre-DAA strategy. 
After disease modelling of the cohort, the post-DAA strat-
egy would avoid 8,667 (63%) cases of DC, 5,471 (53%) cases 
of HCC, 1,137 (59%) LTs and 9,607 (58%) liver disease-relat-
ed deaths compared to the pre-DAA strategy. This would save 
approximately €468 million, 84% of these savings would 
result from the reduced number of LTs and cases of HCC 
following the post-DAA strategy (Table 2). The number of 
avoided events and their associated costs without a discount 
rate applied are shown in table 2 and figures 2 A-D.
Table 1 (Cont.). Parameters used in the modelling of chronic hepatitis C 
Annual health state utility values Cost of the health states
Health states Utility values Reference Costs Reference
SVR F2 (1st year)* 0.93 (23) €112 (27)
SVR F3 (1st year)* 0.86 (23) €112 (27)
SVR F4 (1st year)* 0.83 (23) €161 (27)
Regr. HC 0.86 (23) €112 (27)
DC 0.69 (23) €2,265 (32)
HCC 0.67 (23) €8,629 (32)
LT 0.50 (23) €121,707 (32)
Post-LT 0.77 (23) €35,574 (32)
*The cost of SVR states in subsequent years was €0.00 (SVR F2), €0.00 (SVR F3) and €161.70 (SVR F4). DAA: Direct-acting antiviral; DC: Decompensated cirrhosis; GT: 
Genotype; HCC: Hepatocellular carcinoma; LT: Liver transplant; Post-LT: Post-liver transplant; Regr. HC: Regression of hepatic cirrhosis; SVR: Sustained virologic response. 
Fig. 1. Results of the analysis of the 51,900 patient cohort with the post-
DAA strategy compared to the pre-DAA strategy, applying a discount 
rate of 3% to health costs and outcomes (*costs of disease management 
-fibrosis, cirrhosis, SVR, regression of liver cirrhosis, decompensated cir-
rhosis, hepatocellular carcinoma and liver transplantation. Incremental 
cost post-DAA vs. pre-DAA: €375 million. Incremental QALYs post-DAA 
vs. DAA: 153.970 QALYs. DAA: Direct-acting antiviral; QALYs: quality-
adjusted life year).
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Table 2. Clinical events avoided and cost savings (€, 2016) as a consequence of avoiding events with the post-DAA versus pre-
DAA, with (3%) and without (0%) the discount rate for costs and outcome
Clinical event
Events  
(post-DAA)*
Total cost of 
events (post-DAA)
Events 
(pre-DAA)†
Total costs of 
events (pre-DAA)
Events avoided post-
DAA vs pre-DAA
Cost savings post-
DAA vs pre-DAA‡
Discount rate results (3% for costs and outcomes)
Decompensated cirrhosis 5,112 €42,925,048 13,779 €118,877,981 - 8,667 €75,952,933
Hepatocellular carcinoma 4,781 €82,200,386 10,252 €181,274,045 - 5,471 €99,073,658
Liver transplantation§ 793 €196,329,404 1,930 €489,452,403 - 1,137 €293,122,999
Liver-related death 6,792 ----- 16,400 ----- -9,608 -----
Total €321,454,838 €789,604,429 €468,149,590
Results without discount rate (0% for costs and outcomes)
Decompensated cirrhosis 7,872 €70,021,521 21,465 €190,254,533 -13,593 €120,233,011
Hepatocellular carcinoma 7,403 €129,445,520 16,136 €281,720,163 -8,733 €152,274,642
Liver transplantation§ 1,311 €351,493,029 3,237 €861,443,958 -1,926 €509,950,929
Liver-related death 11,272 ----- 27,659 ----- -16,387 -----
Total €550,960,070 €1,333,418,654 €782,458,582
*In the post-DAA strategy, 73.4% of the patients were treated and 26.6% of the patients did not receive treatment. †In the pre-DAA strategy, 18.9% of the patients were 
treated and 81.1% of the patients did not receive treatment. ‡Cost savings as a consequence of avoiding events with the post-DAA strategy versus the pre-DAA strategy 
during the 50 year modelling in a cohort of 51,900 patients with HCC. §Transplantation and post-Liver transplantation. DAA: Direct-acting antiviral.
Fig. 2. The annual impact on the number of clinical events with the post-DAA vs. pre-DAA strategy in the analysis population, during the 50 year 
simulation without applying a discount rate.
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After running the model for 10 years without applying a 
discount rate and using the post-DAA strategy, 64% of the 
total cohort (51,900) had achieved a SVR, 2.2% had DC, 
1.1% had HCC and 5.3% had died from liver-related causes. 
Significantly fewer patients from the total cohort achieved 
a SVR at 10 years (10.5%) with the pre-DAA strategy. The 
proportion of patients with DC or HCC increased to 6.0% 
and 2.5%, respectively and the mortality rate associated 
with liver disease was 11.6% (Fig. 3 A and B).
Estimation of the monetary value of a QALY  
(cost per QALY: 20,000, 25,000 and 30,000 euros)
The monetary value of the incremental QALYs achieved 
with the post-DAA strategy versus the pre-DAA strategy 
within the cohort using the number of incremental QALYs 
of the baseline case (Fig. 1) ranged from 3,079 to 4,619 
million euros with a value between 20,000 and 30,000 
euros per QALY (Fig. 4).
Sensitivity analysis results
The QALY values ranged between 135,607 and 220,701 
additional QALYs when the OWSA was used to compare 
the post-DAA and pre-DAA strategies. The incremental 
cost ranged between 156 and 594 million Euros. Drug costs 
had the greatest influence on the results in the post-DAA 
strategy, which amounted to €218 million. In contrast, drug 
cost had a lower impact in the pre-DAA strategy (€29 mil-
lion). As all patients in the post-DAA strategy group were 
treated, the increment QALY gain was 220,701 which was 
associated with an incremental cost of €531 million. Modi-
fication of the percentage of patients treated in the pre-DAA 
strategy did not significantly alter the results of the analy-
sis. When minimum values of SVR rates were considered, 
Fig. 3. The evolution (or progression) of the disease of pre-DAA and post-DAA, without applying the discount rate (*Number of patients in a particular 
health state during years 10, 20, 30, 40 and 50. †Accumulated patients from year 0 to 10, 20, 30, 40 and 50. DC: Decompensated cirrhosis; HCC: 
Hepatocellular carcinoma; LT: Liver transplantation; Post-LT: Post-liver transplantation; Regr. HC: Regression of liver cirrhosis).
Fig. 4. Estimates of the monetary value according to different values of 
cost per QALYs obtained with the post-DAA strategy vs. the pre-DAA 
strategy (estimates of the monetary value obtained with the post-DAA 
strategy vs. the pre-DAA strategy in the study population according 
to different cost values per QALYs (€20,000, €25,000 and €30,000), 
compared to the results of the analysis when applying a discount rate of 
3% for costs and outcome. QALY: quality-adjusted life year).
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141,381 and 160,285 QALYs were obtained for the post-
DAA and pre-DAA strategies, respectively. Variations in 
the cost of transplantation were not associated with signif-
icant variations in incremental cost (€27 million).
DISCUSSION
The introduction of oral DAA regimens to treat CHC 
has changed the management of this disease (40). The 
high efficacy and safety of DAAs allow any HCV-infected 
patient to be treated and eventually cured (40). The present 
analysis evaluated long-term health outcomes and costs 
following the implementation of the SPCHC in 2015. The 
results demonstrate that the prevention of clinical events 
related to liver disease and the costs associated with their 
management and the increased quality-adjusted life years 
compensate for the financial investment in drug costs. 
Health resources are limited and must be managed in a 
manner consistent with the needs of a population to ensure 
the sustainability of a health system. One way to manage 
these resources is using value-based health systems, which 
have a fundamental objective of achieving the best health 
outcome for patients at an acceptable and sustainable cost. 
For this to occur, measures must be adopted based on val-
ue and this value is defined from the result obtained per 
monetary unit invested. These measures include estimating 
disease cost, improving and innovating health technolo-
gies, ensuring patient access to innovative treatments with 
disruptive changes over health outcomes and improving 
the general health of the population.
It should be noted that the costs of CHC treatment only 
corresponded to the first year following the implementa-
tion of the SPCHC, as the objective of this analysis was to 
evaluate health outcomes in 2015. The analysis only took 
into account the investment already made and not the cost 
of continuing the SPCHC. As more patients are treated, 
this cost will decrease for various reasons, including reduc-
tions in the number of patients eligible for treatment due 
to the decreased disease prevalence that results from the 
high treatment efficacy of new DAAs, as well as reduc-
tions in treatment costs. This phenomenon has already been 
reflected in the CHC drug expenditure corresponding to 
the second half of 2016, which was 63% lower than that in 
2015 (41). To measure the impact of drug cost change on 
analysis results, an OWSA was performed in which drug 
costs were varied for each treatment strategy (pre-DAA and 
post-DAA). The results of the analysis showed an incre-
mental cost of €218 million. Therefore, the predicted lower 
drug cost in the future would reduce the incremental cost 
and increase the efficiency of the continuation and/or exten-
sion of the treatment strategies presented in the SPCHC.
The effectiveness of new DAAs in treating CHC is evi-
dent and there is a strong level of evidence supporting 
their use in clinical practice. However, whether the bud-
getary impact derived from the use of DAAs translates into 
a worthwhile investment for health systems needs to be 
assessed. It is important to consider that patients with CHC 
who were treated with new DAAs achieved SVR rates of 
> 95% (10-12,18), indicating that most were cured and 
that investing in drugs to treat CHC might be worthwhile. 
Another important factor associated with value systems 
is innovation. In this regard, the measurement and compar-
ison of health outcomes with those obtained from previous 
strategies is essential (42,43). The new DAAs have contrib-
uted to an increase in treatment efficacy and effectiveness, a 
greater tolerability and adherence by patients, a shortening 
of treatment duration and a simpler dosage regimen, which 
is particularly innovative. However, evaluating the efficien-
cy of innovation requires the estimation and association of 
the cost of innovation, which is the relationship between the 
increased SVR rates produced by the new DAAs and their 
cost in this case (44). This relationship must be established 
and compared to drugs previously used as standard thera-
pies. In our analysis, the post-DAA strategy implemented 
in the SPCHC was more cost-effective than the pre-DAA 
strategy from a clinical standpoint. 
The reduced number of LTs for the patients who were 
cured in 2015 represents a savings of €509 million, which 
corresponds to an overall saving of 65% of CHC follow-up 
and complication treatment costs. However, these results 
may underestimate the actual effect, as new evidence sug-
gests that eliminating HCV in patients already on LT waiting 
lists might lead to significant improvements in liver func-
tion, ultimately resulting in patients being withdrawn from 
the waiting list (45). A collateral benefit of the reduction 
in LTs for patients with CHC is the increase in availability 
of livers for organ donation for other indications (46). In 
Spain, 36.4% of all LTs in 2015 were performed in cirrho-
sis patients due to HCV and HCC (47). As the new DAAs 
prevent CHC from progressing to more advanced stages, 
according to our analysis, the number of transplants would 
be expected to be reduced by 46.2% over the next 10 years. 
Our analysis also focused on the monetary value of the 
post-DAA strategy by extrapolating the QALYs achieved 
by the post-DAA strategy compared to the pre-DAA strat-
egy (48). This approach has been used in other health 
evaluations such as the study by Van Nuys et al., which 
evaluated the social benefit in monetary terms from the 
QALYs obtained with new DAAs and from different val-
ues assigned to the efficiency threshold in the treatment 
of HCV-infected patients in the United States (37). In 
the present study, the monetary value associated with the 
increase in QALYs achieved with the post-DAA versus 
pre-DAA strategy (153,981 QALYs) across the patient 
cohort ranged from 3,069 to 4,604 million Euros. This far 
exceeds the cost increase of €375 million. 
In the SPCHC, patients who should have preferential 
access to the new DAAs are defined as those with signif-
icant fibrosis (≥ F2) and those whose treatment cannot be 
deferred. The total number of patients estimated to receive 
treatment was 51,900, and approximately 73% of these 
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patients were treated in 2015 and the remainder was treated 
at the beginning of 2016. A more accurate assessment would 
require real observed data of SVR rates obtained from the 
SPCHC and the evaluation of access for all infected patients, 
including those in the initial stages of fibrosis. This study 
did not include patients in stage F0 or F1 as this was not 
the objective of the study. Future pharmacoeconomic studies 
must include all infected patients in Spain in order to eval-
uate the overall clinical and economic impact of the new 
policies. Furthermore, as our analysis focused on the current 
population of patients who had already received treatment, 
the development and implementation of screening programs 
for the detection of HCV in high-risk groups in order to 
enable their access to curative treatment should be examined 
in future revisions of the SPCHC. On the other hand, the 
modelling here focused only on the first year following the 
implementation of the SPCHC, and the extra-hepatic man-
ifestations associated with CHC, which occur irrespective 
of the stage of liver disease (49) and could increase the total 
disease burden, have not been taken into account (50). Had 
these situations been considered, the difference in efficacy 
and safety between previous and new antivirals would prob-
ably have shown a greater clinical benefit by preventing a 
greater number of liver complications and also extra-hepatic 
complications within the CHC population. 
Another factor that should be considered is the fact 
that this analysis was conducted from the perspective of 
the National Health System and not from a societal per-
spective. Thus, the productivity loss of CHC patients was 
not considered. This is relevant as the CHC population is 
mostly a working age population (50). Prior studies on 
work productivity associated with HCV infection have 
confirmed that CHC patients show high rates of absentee-
ism and that their work productivity significantly deteri-
orates (50). This deterioration does not affect treated and 
untreated patients equally as different treatments impact to 
a greater or lesser extent on productivity due to the vari-
ability in adverse events. In economic terms, this translates 
into increased indirect costs resulting from lost working 
hours as well as increased direct costs due to factors such 
as increased consumption of health resources (50). These 
costs may be added to the cost of premature deaths due to 
CHC, which has been estimated at €1,054 million over a 
period of three years (51). Only direct costs were incorpo-
rated in our analysis and any costs associated with the loss 
of productivity were excluded. Had these latter costs been 
included, it would have significantly increased the total 
cost of the pre-DAA strategy due to the low percentage 
of patients treated and their poorer health status compared 
with those treated with the post-DAA strategy.
CONCLUSION
To ensure the sustainability of the healthcare system, 
prioritizing care for patients in more advanced stages of 
disease is crucial and the subsequent establishment of a 
treatment strategy for all patients, regardless of their fibro-
sis stage. The present economic evaluation demonstrates 
that the use of DAA-based treatments for CHC patients in 
Spain would significantly reduce the morbidity and mor-
tality associated with the disease and thus represents an 
efficient use of public resources. Despite the initial dis-
bursement allocated to the acquisition of new treatments, 
the current treatment strategy for the population classified 
as a priority in the SPCHC (post-DAA) increases long-
term societal value and guarantees sustainability of the 
National Health System. 
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